1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Urethral Cancer Global Clinical Trials Review, H1, 2014

Urethral Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Urethral Cancer Global Clinical Trials Review, H1, 2014" provides data on the Urethral Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Urethral Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Urethral Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Urethral Cancer Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Urethral Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Urethral Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Urethral Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Unaccomplished Trials of Urethral Cancer 23
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Urethral Cancer Therapeutics Clinical Trials 28
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Oncogenex Pharmaceuticals, Inc. 31
Clinical Trial Overview of Oncogenex Pharmaceuticals, Inc. 31
MethylGene Inc. 32
Clinical Trial Overview of MethylGene Inc. 32
Merck and Co., Inc. 33
Clinical Trial Overview of Merck and Co., Inc. 33
Eli Lilly and Company 34
Clinical Trial Overview of Eli Lilly and Company 34
Eisai Co., Ltd. 35
Clinical Trial Overview of Eisai Co., Ltd. 35
AstraZeneca PLC 36
Clinical Trial Overview of AstraZeneca PLC 36
Altor BioScience Corporation 37
Clinical Trial Overview of Altor BioScience Corporation 37
Clinical Trial Overview of Top Institutes / Government 38
National Cancer Institute 38
Clinical Trial Overview of National Cancer Institute 38
Southwest Oncology Group 40
Clinical Trial Overview of Southwest Oncology Group 40
The University of Texas M. D. Anderson Cancer Center 41
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 41
Memorial Sloan Kettering Cancer Center 42
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 42
Eastern Cooperative Oncology Group 43
Clinical Trial Overview of Eastern Cooperative Oncology Group 43
European Organization for Research and Treatment of Cancer 44
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 44
The Wales Cancer Trials Unit 45
Clinical Trial Overview of The Wales Cancer Trials Unit 45
Medical Research Council 46
Clinical Trial Overview of Medical Research Council 46
Wake Forest University 47
Clinical Trial Overview of Wake Forest University 47
University of Southern California 48
Clinical Trial Overview of University of Southern California 48
Five Key Clinical Profiles 49
Appendix 107
Abbreviations 107
Definitions 107
Research Methodology 108
Secondary Research 108
About GlobalData 109
Contact Us 109
Disclaimer 109
Source 110

List of Tables
Urethral Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Urethral Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Urethral Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Urethral Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Urethral Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Urethral Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Urethral Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Urethral Cancer Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Urethral Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Urethral Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Urethral Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Urethral Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Urethral Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 19
Urethral Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 20
Urethral Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Urethral Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Urethral Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 23
Urethral Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 23
Urethral Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 24
Urethral Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Urethral Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 26
Urethral Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Urethral Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Urethral Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Oncogenex Pharmaceuticals, Inc., 2014* 31
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by MethylGene Inc., 2014* 32
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 33
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 34
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Co., Ltd., 2014* 35
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 36
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Altor BioScience Corporation, 2014* 37
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 38
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 40
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 41
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 42
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2014* 43
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 44
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The Wales Cancer Trials Unit, 2014* 45
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical Research Council, 2014* 46
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Wake Forest University, 2014* 47
Urethral Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Southern California, 2014* 48

List of Figures
Urethral Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Urethral Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Urethral Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Urethral Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Urethral Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Urethral Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Urethral Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Proportion of Urethral Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Urethral Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Urethral Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Urethral Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Urethral Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 19
Urethral Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 20
Urethral Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Urethral Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Urethral Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Urethral Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 26
Urethral Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Urethral Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Urethral Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 108

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecast to 2025

OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecast to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecast to 2025 Summary Endometriosis is an estrogen-dependent, chronic, inflammatory disease characterized by the appearance and growth of ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.